Trials / Completed
CompletedNCT00622258
A Phase I Dose Escalation Study of RAD001 Administered in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This study assesses the tolerability, safety, efficacy and pharmacokinetics of everolimus in Japanese patients. Everolimus is administered orally everyday to adult patients with relapsed or refractory non-Hodgkin's lymphoma who have progressed despite standard therapy or for whom standard systemic therapy dose not exist.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Everolmus |
Timeline
- Start date
- 2008-03-01
- Primary completion
- 2014-01-01
- Completion
- 2014-01-01
- First posted
- 2008-02-22
- Last updated
- 2020-12-21
Locations
8 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00622258. Inclusion in this directory is not an endorsement.